This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Halliday, W. J. Search for Related Content PubMed PubMed Citation Articles by Halliday, W. J.

Historical Background and Aspects of the Mechanism of Leukocyte Adherence Inhibition

Department of Microbiology, University of Queensland, Brisbane, Australia

The development of leukocyte adherence inhibition is traced from early experiments with murine tumors to recent applications in human cancer and in cell-mediated immunity in general.

Arbitrary experimental conditions (serum in culture medium, preincubation, and tumor extracts at a single concentration) were initially set up and permitted detection of specific inhibition of adherence of sensitized leukocytes reacting with antigen of the tumor extracts. Blocking serum completely or partially restored adherence.

It was readily demonstrated that leukocyte adherence inhibition was mediated by a soluble lymphokine-like factor [leukocyte adherence inhibition factor (LAIF)]. Recent studies suggest that serum is important in enabling detection of LAIF; this may explain the inability of some other workers to confirm our findings. Serum appears to protect LAIF from enzymatic destruction in mixtures containing tumor extracts.

Complex cell interactions are involved in LAIF production. With mouse cells in vitro, macrophages are required for production by both T- and B-lymphocytes, and there is evidence for suppressor cells also.

¹ Presented at the International Workshop on Leukocyte Adherence Inhibition, May 15 to 17, 1978, Buffalo, N. Y. This research has been supported from the beginning by National Health and Medical Research Council of Australia and the Queensland Cancer Fund.